Podcast: ESMO26: Major readouts from the 2026 congress
This week's podcast features the Clinical Trials Arena team and GlobalData analysts who discuss the biggest study readouts from the ESMO Congress 2026.
Therapy Area
ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial
ESMO26: KEYNOTE-C93 backs chemo-free Keytruda in dMMR endometrial cancer
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open
ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer
Women’s health landscape shifting, but systemic hurdles remain
Podcast: Key takeaways from EASD 2026 on where GLP-1s are headed
